Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study

BACKGROUND: There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)–positive breast cancer recurrence after perioperative treatment with TZM. AIM: To clarify the outcome and safety of TZM r...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashiro, Hiroyasu, Sawaki, Masataka, Masuda, Norikazu, Okumura, Yasuhiro, Takano, Toshimi, Tokunaga, Eriko, Saito, Tsuyoshi, Sagara, Yasuaki, Yamazaki, Kosuke, Kawaguchi, Yoshihiro, Lee, Tecchuu, Ozaki, Shinji, Yamagami, Kazuhiko, Yamamoto, Naohito, Kuroi, Katsumasa, Suwa, Hirofumi, Ohtani, Shoichiro, Ito, Toshikazu, Yasuno, Shinji, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043925/
https://www.ncbi.nlm.nih.gov/pubmed/30013356
http://dx.doi.org/10.1177/1178223418786243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043925/
https://www.ncbi.nlm.nih.gov/pubmed/30013356
http://dx.doi.org/10.1177/1178223418786243

Ejemplares similares